Low-dose bromocriptine therapy in Parkinson's disease: Double-blind, placebo-controlled study

AL Staal-Schreinemachers*, H Wesseling, DJ Kamphuis, W van der Burg, JPWF Lakke

*Corresponding author for this work

    Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

    29 Citations (Scopus)

    Abstract

    Twenty-one de novo parkinsonian patients in stage I to III of the Hoehn and Yahr scale completed a 6-month, double-blind, placebo-controlled study. Low-dose bromocriptine (15 mg daily) was effective. Rigidity improved more than tremor or bradykinesia. Sustained satisfactory benefit was seen only in patients with mild Parkinson's disease.
    Original languageEnglish
    Pages (from-to)291-293
    Number of pages3
    JournalNeurology
    Volume36
    Issue number2
    DOIs
    Publication statusPublished - Feb-1986

    Fingerprint

    Dive into the research topics of 'Low-dose bromocriptine therapy in Parkinson's disease: Double-blind, placebo-controlled study'. Together they form a unique fingerprint.

    Cite this